Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HY 004

Next Previous
Search
Drug Profile

HY 004

Alternative Names: HY-004; HY-004B8b

Latest Information Update: 23 Mar 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helperby Therapeutics
  • Class Antibacterials; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 23 Mar 2021 HY 004 is still in phase II trials for Methicillin-resistant Staphylococcus aureus infections (Prevention) in United Kingdom (Topical)
  • 15 Jun 2020 Helperby Therapeutics completes a phase II trial in Methicillin-resistant Staphylococcus aureus infections (Prevention) in United Kingdom (Topical), before June 2020 (Helperby Therapeutics pipeline, June 2020)
  • 10 Sep 2018 Helperby Therapeutics intends to launch HY 004 in 2022 (Helperby Therapeutics website, September 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top